Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Activates coagulation factor XI (F11); activation is promoted by the contact with negatively charged surfaces (PubMed:2019570, PubMed:21976677).
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL8/CXCL8, in endothelial cells (PubMed:30568593, PubMed:9780208)
Heterodimer (named alpha-thrombin) of a light and a heavy chain; disulfide-linked. Forms a heterodimer with SERPINA5. In plasma, interacts (via N-terminus) with alpha-1-microglobulin with molar ratio 1:2 and 1:1; this interaction does not prevent the activation of prothrombin to thrombin.
Interacts (thrombin) with iripin-8, a serine protease inhibitor from Ixodes ricinus saliva (PubMed:34502392). Interacts (thrombin) with iripin-3, a serine protease inhibitor from Ixodes ricinus saliva (PubMed:33732248). Interacts (thrombin) with Anopheles albimanus salivary thrombin inhibitor anophelin; the interaction results in thrombin inhibition (PubMed:23223529).
Interacts (thrombin) with Anopheles gambiae salivary thrombin inhibitor anophelin; the interaction results in thrombin inhibition (PubMed:28592490). Interacts (thrombin) with Amblyomma variegatum variegin; the interaction results in thrombin inhibition (PubMed:22053189). Interacts (thrombin) with Xenopsylla cheopis salivary thrombin inhibitor XC-42 (PubMed:34688666).
Interacts (thrombin) with Xenopsylla cheopis salivary thrombin inhibitor XC-43 (PubMed:34688666)
Expressed by the liver and secreted in plasma
A very rare blood coagulation disorder characterized by mucocutaneous bleeding symptoms. The severity of the bleeding manifestations correlates with blood factor II levels.
A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
A multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
A common complication of pregnancy, resulting in spontaneous abortion before the fetus has reached viability. The term includes all miscarriages from the time of conception until 24 weeks of gestation. Recurrent pregnancy loss is defined as 3 or more consecutive spontaneous abortions.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to ARHGEF26, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 41
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT05590533 | Cultural Adaptation, Reliability, Validity, Multiple Sclerosis, Fatigue | Turkish Version of F-2-MS | N/A | UNKNOWN |
| NCT02466516 | Non-Alcoholic Steatohepatitis (NASH) | Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 | PHASE2 | COMPLETED |
| NCT06632444 | Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis | LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | PHASE3 | RECRUITING |
| NCT07316842 | Viral Hepatitis C | SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF | N/A | ACTIVE_NOT_RECRUITING |
| NCT01125501 | Metabolic Syndrome | Protandim and the Metabolic Syndrome | NA | WITHDRAWN |
| NCT07102316 | Healthy Volunteers | A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants | PHASE1 | COMPLETED |
| NCT04026009 | Clostridium Infections | Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years | PHASE1 | COMPLETED |
| NCT04849728 | NASH - Nonalcoholic Steatohepatitis | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | PHASE3 | ACTIVE_NOT_RECRUITING |
| NCT00385931 | Hypertension, Hypercholesterolemia, Dyslipidemia | Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin | PHASE3 | COMPLETED |
| NCT05147090 | Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver, Empagliflozin, SGLT2 Inhibitors | Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients | PHASE4 | ACTIVE_NOT_RECRUITING |